Your English writing platform
Discover LudwigExact(25)
Sixteen treatment failures (24.2%) were observed during a median follow-up period of 63.3 weeks (IQR, 44.7 103.1), including 13 persisting infections, 1 relapse after treatment disruption, and 2 super-infections.
During follow-up there was 1 relapse in each of the treatment groups, giving final cure rates of 48 of 52 (92·3%) for PM12 + SB, 45 of 48 (93·8%) for PM18 + SB, and 26 of 49 (53·1%) for SB.
In contrast, 7 of 12 patients (58%) relapsed (6 CD19+ relapses, 1 CD19− relapse) post-CAR-T cell infusion in the cohort without Flu.
As a consequence of these enhancements, an improvement in overall and disease-free survival also was observed in the Cy/Flu cohort, wherein only 2 of 17 (12%) patients relapsed (1 CD19+ relapse, 1 CD19− relapse) post-CAR-T cell infusion.
In 1 relapse for MCA and for CEA the tumour marker increase was the only sign.
In group 2, there was 1 relapse of infection (Table 3).
Similar(35)
The statistical end points in our analysis were (1) relapse-free survival (primary end point) and, (2) overall survival of patients.
Of 16 children with MYCNA, 7 were stage 1 (5 relapses and 4 deaths) and 9 were stage 2 (3 relapses and 2 deaths) patients.
Pooling this series of patients with all 24 relapsing patients from group 1 (17 relapses at 5 years and seven beyond 5 years) yield a group of 46 patients.
In general, patients with ≥1 relapse per year, absence of complete recovery from relapses, sustained disability progression of ≥1 and MRI progression, with or without clinical signs, are considered as 'treatment non-responders', justifying the transition from basic to escalation therapy [9].
Of those, around 40 relapse.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com